SMO has been identified as a potential drug target in osteosarcoma, as its inhibitor cyclopamine promotes G1 arrests and represses expression of cyclin D1, cyclin E1, SKP2, and pRb[35]. Here, CCNE1 is linked to osteosarcoma.